 |
|
|
REFERENCES
601.
van Beem H, Manger FW, van Boxtel C, van Bentem
N: Etomidate anaesthesia in patients with cirrhosis of the liver: Pharmacokinetic
data. Anaesthesia 38(Suppl):61–62, 1983.
602.
Arden JR, Holley FO, Stanski DR: Increased sensitivity
to etomidate in the elderly: Initial distribution versus altered brain response.
Anesthesiology 65:19–27, 1986.
603.
Doenicke A, Loffler B, Kugler J, et al: Plasma
concentration and E.E.G. after various regimens of etomidate. Br J Anaesth 54:393–400,
1982.
604.
Evans RH, Hill RG: The GABA-mimetic action of
etomidate [proceedings]. Br J Pharmacol 61:484P, 1977.
605.
Lingamaneni R, Hemmings HC Jr: Differential interaction
of anaesthetics and antiepileptic drugs with neuronal Na+
channels, Ca2+
channels, and GABA(A) receptors. Br J Anaesth 90:199–211, 2003.
606.
Blednov YA, Jung S, Alva H, et al: Deletion of
the alpha1 or beta2 subunit of GABAA
receptors reduces actions of alcohol
and other drugs. J Pharmacol Exp Ther 304:30–36, 2003.
607.
Cold GE, Eskesen V, Eriksen H, et al: CBF and
CMRO2
during continuous etomidate infusion supplemented with N2
O
and fentanyl in patients with supratentorial cerebral tumour. A dose-response study.
Acta Anaesthesiol Scand 29:490–494, 1985.
608.
Dearden NM, McDowall DG: Comparison of etomidate
and althesin in the reduction of increased intracranial pressure after head injury.
Br J Anaesth 57:361–368, 1985.
609.
Modica PA, Tempelhoff R: Intracranial pressure
during induction of anaesthesia and tracheal intubation with etomidate-induced EEG
burst suppression. Can J Anaesth 39:236–241, 1992.
610.
Renou AM, Vernhiet J, Macrez P, et al: Cerebral
blood flow and metabolism during etomidate anaesthesia in man. Br J Anaesth 50:1047–1051,
1978.
611.
Tulleken CA, van Dieren A, Jonkman J, Kalenda
Z: Clinical and experimental experience with etomidate as a brain protective agent.
J Cereb Blood Flow Metab 2(Suppl 1):S92–S97, 1982.
612.
Sano T, Patel PM, Drummond JC, Cole DJ: A comparison
of the cerebral protective effects of etomidate, thiopental, and isoflurane in a
model of forebrain ischemia in the rat. Anesth Analg 76:990–997, 1993.
613.
Drummond JC, Cole DJ, Patel PM, Reynolds LW:
Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental:
A comparison of the extent of cerebral injury. Neurosurgery 37:742–748, discussion
748–749, 1995.
614.
Guo J, White JA, Batjer HH: Limited protective
effects of etomidate during brainstem ischemia in dogs. J Neurosurg 82:278–283,
1995.
615.
Thomson MF, Brock-Utne JG, Bean P, et al: Anaesthesia
and intra-ocular pressure: A comparative of total intravenous anaesthesia using
etomidate with conventional inhalation anaesthesia. Anaesthesia 37:758–761,
1982.
616.
Ghoneim MM, Yamada T: Etomidate: A clinical
and electroencephalographic comparison with thiopental. Anesth Analg 56:479–485,
1977.
617.
Lees NW, Hendry JG: Etomidate in urological outpatient
anaesthesia. A clinical evaluation. Anaesthesia 32:592–597, 1977.
618.
Ebrahim ZY, DeBoer GE, Luders H, et al: Effect
of etomidate on the electroencephalogram of patients with epilepsy. Anesth Analg
65:1004–1006, 1986.
619.
Gancher S, Laxer KD, Krieger W: Activation of
epileptogenic activity by etomidate. Anesthesiology 61:616–618, 1984.
620.
Reddy RV, Moorthy SS, Dierdorf SF, et al: Excitatory
effects and electroencephalographic correlation of etomidate, thiopental, methohexital,
and propofol. Anesth Analg 77:1008–1011, 1993.
621.
Thornton C, Heneghan CP, Navaratnarajah M, et
al: Effect of etomidate on the auditory evoked response in man. Br J Anaesth 57:554–561,
1985.
622.
McPherson RW, Sell B, Traystman RJ: Effects of
thiopental, fentanyl, and etomidate on upper extremity somatosensory evoked potentials
in humans. Anesthesiology 65:584–589, 1986.
623.
Kalkman CJ, Drummond JC, Ribberink AA, et al:
Effects of propofol, etomidate, midazolam, and fentanyl on motor evoked responses
to transcranial electrical or magnetic stimulation in humans. Anesthesiology 76:502–509,
1992.
624.
Guldager H, Sondergaard I, Jensen FM, Cold G:
Basophil histamine release in asthma patients after in vitro provocation with Althesin
and etomidate. Acta Anaesthesiol Scand 29:352–353, 1985.
625.
Kay B: The measurement of occlusion pressure
during anaesthesia. A comparison of the depression of respiratory drive by methohexitone
and etomidate. Anaesthesia 34:543–548, 1979.
626.
Morgan M, Lumley J, Whitwam JG: Respiratory effects
of etomidate. Br J Anaesth 49:233–236, 1977.
627.
Criado A, Maseda J, Navarro E, et al: Induction
of anaesthesia with etomidate: Haemodynamic study of 36 patients. Br J Anaesth
52:803–806, 1980.
628.
Ouedraogo N, Marthan R, Roux E: The effects of
propofol and etomidate on airway contractility in chronically hypoxic rats. Anesth
Analg 96:1035–1041, 2003.
629.
Ogawa K, Tanaka S, Murray PA: Inhibitory effects
of etomidate and ketamine on endothelium-dependent relaxation in canine pulmonary
artery. Anesthesiology 94:668–677, 2001.
630.
Lindeburg T, Spotoft H, Bredgaard Sorensen M,
Skovsted P: Cardiovascular effects of etomidate used for induction and in combination
with fentanyl-pancuronium for maintenance of anaesthesia in patients with valvular
heart disease. Acta Anaesthesiol Scand 26:205–208, 1982.
631.
Haessler R, Madler C, Klasing S: Propofol/fentanyl
versus etomidate/fentanyl for the induction of anesthesia in patients with aortic
insufficiency and coronary artery disease. J Cardiothorac Vasc Anesth 6:173, 1992.
632.
Sprung J, Ogletree-Hughes ML, Moravec CS: The
effects of etomidate on the contractility of failing and nonfailing human heart muscle.
Anesth Analg 91:68–75, 2000.
633.
Lischke V, Wilke HJ, Probst S, et al: Prolongation
of the QT-interval during induction of anesthesia in patients with coronary artery
disease. Acta Anaesthesiol Scand 38:144–148, 1994.
634.
de Bruijn NP, Hlatky MA, Jacobs JR, et al: General
anesthesia during percutaneous transluminary coronary angioplasty for acute myocardial
infarction: Results of a randomized controlled clinical trial. Anesth Analg 68:201–207,
1989.
635.
Gries A, Weis S, Herr A, et al: Etomidate and
thiopental inhibit platelet function in patients undergoing infrainguinal vascular
surgery. Acta Anaesthesiol Scand 45:449–457, 2001.
636.
Ledingham I, Finlay W, Watt I: Etomidate and
adrenocortical function [letter]. Lancet 2:1434, 1983.
637.
Allolio B, Dorr H, Stuttmann R, et al: Effect
of a single bolus dose of etomidate upon eight major corticosteroid hormones and
plasma ACTH: Clin Endocrinol (Oxf) 22:281–286, 1985.
638.
Lamberts SW, Bons EG, Bruining HA, de Jong FH:
Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole
and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical
cells. J Pharmacol Exp Ther 240:259–264, 1987.
639.
Boidin MP: Steroid response to ACTH and to ascorbinic
acid during infusion of etomidate for general surgery. Acta Anaesthesiol Belg 36:15–22,
1985.
640.
Boidin MP, Erdmann WE, Faithfull NS: The role
of ascorbic acid in etomidate toxicity. Eur J Anaesthesiol 3:417–422, 1986.
641.
Wagner RL, White PF, Kan PB, et al: Inhibition
of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 310:1415–1421,
1984.
642.
Duthie DJ, Fraser R, Nimmo WS: Effect of induction
of anaesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth 57:156–159,
1985.
643.
Crozier TA, Beck D, Schlaeger M, et al: Endocrinological
changes following etomidate, midazolam, or methohexital for minor surgery. Anesthesiology
66:628–635, 1987.
644.
Fragen R, Shanks C, Molteni A: Effect on plasma
cortisol concentration of a single induction dose of etomidate or thiopentone. Lancet
2:625, 1983.
645.
Crozier TA, Schlaeger M, Wuttke W, Kettler D:
TIVA with etomidate-fentanyl versus midazolam-fentanyl. The perioperative stress
of coronary surgery overcomes the inhibition of cortisol synthesis caused by etomidate-fentanyl
anesthesia [in German]. Anaesthesist 43:605–613, 1994.
646.
Famewo CE: Induction of anaesthesia with etomidate
in a patient with acute intermittent porphyria. Can Anaesth Soc J 32:171–173,
1985.
647.
St Pierre M, Dunkel M, Rutherford A, Hering W:
Does etomidate increase postoperative nausea? A double-blind controlled comparison
of etomidate in lipid emulsion with propofol for balanced anaesthesia. Eur J Anaesthesiol
17:634–641, 2000.
648.
Korttila K, Aromaa U: Venous complications after
intravenous injection of diazepam, flunitrazepam, thiopentone and etomidate. Acta
Anaesthesiol Scand 24:227–230, 1980.
649.
Galloway PA, Nicoll JM, Leiman BC: Pain reduction
with etomidate injection. Anaesthesia 37:352–353, 1982.
650.
Doenicke AW, Roizen MF, Hoernecke R, et al: Solvent
for etomidate may cause pain and adverse effects. Br J Anaesth 83:464–466,
1999.
651.
Olkkola KT, Tammisto T: Quantitation of the interaction
of rocuronium bromide with etomidate, fentanyl, midazolam, propofol, thiopentone,
and isoflurane using closed-loop feedback control of infusion of rocuronium. Eur
J Anaesthesiol Suppl 9:99–100, 1994.
652.
Olkkola KT, Tammisto T: Quantifying the interaction
of rocuronium (Org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental,
and isoflurane using closed-loop feedback control of rocuronium infusion. Anesth
Analg 78:691–696, 1994.
653.
Van de Wiele B, Rubinstein E, Peacock W, Martin
N: Propylene glycol toxicity caused by prolonged infusion of etomidate. J Neurosurg
Anesthesiol 7:259–262, 1995.
654.
Liem TH, Booij LH, Hasenbos MA, Gielen MJ: Coronary
artery bypass grafting using two different anesthetic techniques: Part I: Hemodynamic
results. J Cardiothorac Vasc Anesth 6:148–155, 1992.
655.
Shulman MS, Edelmann R: Use of etomidate for
elective cardioversion. Anesthesiology 68:656, 1988.
656.
Batjer HH, Frankfurt AI, Purdy PD, et al: Use
of etomidate, temporary arterial occlusion, and intraoperative angiography in surgical
treatment of large and giant cerebral aneurysms. J Neurosurg 68:234–240, 1988.
657.
Lees NW, Glasser J, McGroarty FJ, Miller BM:
Etomidate and fentanyl for maintenance of anaesthesia. Br J Anaesth 53:959–961,
1981.
658.
Avramov MN, Husain MM, White PF: The comparative
effects of methohexital, propofol, and etomidate for electroconvulsive therapy.
Anesth Analg 81:596–602, 1995.
659.
Maze M, Tranquilli W: Alpha-2 adrenoceptor agonists:
Defining the role in clinical anesthesia. Anesthesiology 74:581–605, 1991.
660.
Kaukinen S, Kaukinen L, Eerola R: Preoperative
and postoperative use of clonidine with neurolept anaesthesia. Acta Anaesthesiol
Scand 23:113–120, 1979.
661.
Kaukinen S, Pyykko K: The potentiation of halothane
anaesthesia by clonidine. Acta Anaesthesiol Scand 23:107–111, 1979.
662.
Bloor BC, Flacke WE: Reduction in halothane anesthetic
requirement by clonidine, an alpha-adrenergic agonist. Anesth Analg 61:741–745,
1982.
663.
De Wolf AM, Fragen RJ, Avram MJ, et al: The pharmacokinetics
of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 93:1205–1209,
2001.
664.
Guo TZ, Jiang JY, Buttermann AE, Maze M: Dexmedetomidine
injection into the locus ceruleus produces antinociception. Anesthesiology 84:873–881,
1996.
665.
Nelson LE, Lu J, Guo T, et al: The alpha2-adrenoceptor
agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert
its sedative effects. Anesthesiology 98:428–436, 2003.
666.
Nacif-Coelho C, Correa-Sales C, Chang LL, Maze
M: Perturbation of ion channel conductance alters the hypnotic response to the alpha
2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat. Anesthesiology
81:1527–1534, 1994.
667.
Aho M, Erkola O, Kallio A, et al: Comparison
of dexmedetomidine and midazolam sedation and antagonism of dexmedetomidine with
atipamezole. J Clin Anesth 5:194–203, 1993.
668.
Reid K, Hayashi Y, Guo TZ, et al: Chronic administration
of an alpha 2 adrenergic agonist desensitizes rats to the anesthetic effects of dexmedetomidine.
Pharmacol Biochem Behav 47:171–175, 1994.
669.
Maccioli GA: Dexmedetomidine to facilitate drug
withdrawal. Anesthesiology 98:575–577, 2003.
670.
Davies MF, Haimor F, Lighthall G, Clark JD: Dexmedetomidine
fails to cause hyperalgesia after cessation of chronic administration. Anesth Analg
96:195–200, 2003.
671.
Hayashi Y, Guo TZ, Maze M: Hypnotic and analgesic
effects of the alpha 2-adrenergic agonist dexmedetomidine in morphine-tolerant rats.
Anesth Analg 83:606–610, 1996.
672.
Maier C, Steinberg GK, Sun GH, et al: Neuroprotection
by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral
ischemia. Anesthesiology 79:306–312, 1993.
673.
Talke P, Tong C, Lee HW, et al: Effect of dexmedetomidine
on lumbar cerebrospinal fluid pressure in humans. Anesth Analg 85:358–364,
1997.
674.
Karlsson BR, Forsman M, Roald OK, et al: Effect
of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow
and oxygen consumption during halothane anesthesia in dogs. Anesth Analg 71:125–129,
1990.
675.
Zornow MH, Fleischer JE, Scheller MS, et al:
Dexmedetomidine, an alpha 2-adrenergic agonist, decreases cerebral blood flow in
the isoflurane-anesthetized dog. Anesth Analg 70:624–630, 1990.
676.
Zornow MH, Maze M, Dyck JB, Shafer SL: Dexmedetomidine
decreases cerebral blood flow velocity in humans. J Cereb Blood Flow Metab 13:350–353,
1993.
677.
Prielipp RC, Wall MH, Tobin JR, et al: Dexmedetomidine-induced
sedation in volunteers decreases regional and global cerebral blood flow. Anesth
Analg 95:1052–1059, 2002.
678.
Mirski MA, Rossell LA, McPherson RW, Traystman
RJ: Dexmedetomidine decreases seizure threshold in a rat model of experimental generalized
epilepsy. Anesthesiology 81:1422–1428, 1994.
679.
Halonen T, Kotti T, Tuunanen J, et al: Alpha
2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions
and neuronal damage. Brain Res 693:217–224, 1995.
680.
Weinger MB, Segal IS, Maze M: Dexmedetomidine,
acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity
in the rat. Anesthesiology 71:242–249, 1989.
681.
Scheinin H, Karhuvaara S, Olkkola KT, et al:
Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clin Pharmacol
Ther 52:537–546, 1992.
682.
Karhuvaara S, Kallio A, Koulu M, et al: No involvement
of alpha 2-adrenoceptors in the regulation of basal prolactin secretion in healthy
men. Psychoneuroendocrinology 15:125–129, 1990.
683.
Ebert TJ, Hall JE, Barney JA, et al: The effects
of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology
93:382–394, 2000.
684.
Yung-Wei H, Robertson K, Young C, et al: Compare
the respiratory effects of remifentanil and dexmedetomidine. Anesthesiology 95:A1357,
2001.
685.
Arain SR, Ebert TJ: The efficacy, side effects,
and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative
sedation. Anesth Analg 95:461-466, 2002.
686.
Dyck JB, Maze M, Haack C, et al: The pharmacokinetics
and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride
in adult human volunteers. Anesthesiology 78:813–820, 1993.
687.
Hogue CW Jr, Talke P, Stein PK, et al: Autonomic
nervous system responses during sedative infusions of dexmedetomidine. Anesthesiology
97:592–598, 2002.
688.
Roekaerts P, Prinzen F, Willingers H: The effect
of dexmedetomidine on systemic haemodynamics, regional myocardial function and blood
flow during coronary artery stenosis in acute anaesthetized dogs. J Cardiothorac
Anesth 8:58, 1994.
689.
Willigers HM, Prinzen FW, Roekaerts PM, et al:
Dexmedetomidine decreases perioperative myocardial lactate release in dogs. Anesth
Analg 96:657–764, 2003.
690.
Karhuvaara S, Kallio A, Salonen M, et al: Rapid
reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers.
Br J Clin Pharmacol 31:160–165, 1991.
691.
Aantaa RE, Kanto JH, Scheinin M, et al: Dexmedetomidine
premedication for minor gynecologic surgery. Anesth Analg 70:407–413, 1990.
692.
Aantaa R, Kanto J, Scheinin M, et al: Dexmedetomidine,
an alpha 2-adrenoceptor agonist, reduces anesthetic requirements for patients undergoing
minor gynecologic surgery. Anesthesiology 73:230–235, 1990.
693.
Aho M, Lehtinen AM, Erkola O, et al: The effect
of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane
requirements in patients undergoing abdominal hysterectomy. Anesthesiology 74:997–1002,
1991.
694.
Venn RM, Grounds RM: Comparison between dexmedetomidine
and propofol for sedation in the intensive care unit: Patient and clinician perceptions.
Br J Anaesth 87:684–690, 2001.
695.
Triltsch AE, Welte M, von Homeyer P, et al: Bispectral
index-guided sedation with dexmedetomidine in intensive care: A prospective, randomized,
double blind, placebo-controlled phase II study. Crit Care Med 30:1007-1014, 2002.
696.
Flacke JW, Bloor BC, Flacke WE, et al: Reduced
narcotic requirement by clonidine with improved hemodynamic and adrenergic stability
in patients undergoing coronary bypass surgery. Anesthesiology 67:11–19, 1987.
697.
Ghignone M, Quintin L, Duke PC, et al: Effects
of clonidine on narcotic requirements and hemodynamic response during induction of
fentanyl anesthesia and endotracheal intubation. Anesthesiology 64:36–42,
1986.
698.
Segal IS, Jarvis DJ, Duncan SR, et al: Clinical
efficacy of oral-transdermal clonidine combinations during the perioperative period.
Anesthesiology 74:220–225, 1991.
699.
Lieper D, Townsend G: Improved hemodynamic and
renal function with clonidine in coronary artery bypass grafting. Anesth Analg 70:S240,
1990.
700.
Ghignone M, Noe C, Calvillo O, Quintin L: Anesthesia
for ophthalmic surgery in the elderly: The effects of clonidine on intraocular pressure,
perioperative hemodynamics, and anesthetic requirement. Anesthesiology 68:707–716,
1988.
701.
Jaakola ML, Ali-Melkkila T, Kanto J, et al: Dexmedetomidine
reduces intraocular pressure, intubation responses and anaesthetic requirements in
patients undergoing ophthalmic surgery. Br J Anaesth 68:570–575, 1992.
702.
Scheinin B, Lindgren L, Randell T, et al: Dexmedetomidine
attenuates sympathoadrenal responses to tracheal intubation and reduces the need
for thiopentone and preoperative fentanyl. Br J Anaesth 68:126–131, 1992.
703.
Aho M, Erkola O, Kallio A, et al: Dexmedetomidine
infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy.
Anesth Analg 75:940–946, 1992.
704.
Salmenpera MT, Szlam F, Hug CC Jr: Anesthetic
and hemodynamic interactions of dexmedetomidine and fentanyl in dogs. Anesthesiology
80:837–846, 1994.
705.
Talke P, Li J, Jain U, et al: Effects of perioperative
dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative
Ischemia Research Group. Anesthesiology 82:620–633, 1995.
706.
Laborit H, Huguenard P: Practique de l'Hibernotherapie
en Chirurgie et en Medicine. Paris, Masson, 1954.
707.
Laborit H: Stress and Cellular Function. Philadelphia,
JB Lippincott, 1959.
708.
Corssen G, Reves J, Stanley T: Neuroleptanalgesia
and neurolept-anesthesia. In Corssen G, Reves J,
Stanley T (eds): Intravenous Anesthesia and Analgesia. Philadelphia, Lea &
Febiger, 1988, p 175.
709.
Janssen PA: The pharmacology of haloperidol.
Int J Neuropsychiatry 3(Suppl 1):10–18, 1967.
710.
De Castro J, Mundeleer P: Anesthesie sans barbituriques:
La neuroleptanalgesie (R1407, R1625, hydergine, procain). Anesth Analg 42:1022,
1959.
711.
Scuderi PE: Droperidol: Many questions, few
answers. Anesthesiology 98:289–290, 2003.
712.
Dershwitz M: Droperidol: Should the black box
be light gray? J Clin Anesth 14:598–603, 2002.
713.
White PF: Droperidol: A cost-effective antiemetic
for over thirty years. Anesth Analg 95:789–790, 2002.
714.
Gan TJ, Alexander R, Fennelly M, Rubin AP: Comparison
of different methods of administering droperidol in patient-controlled analgesia
in the prevention of postoperative nausea and vomiting. Anesth Analg 80:81–85,
1995.
715.
Gan TJ, White PF, Scuderi PE, et al: FDA "black
box" warning regarding use of droperidol for postoperative nausea and vomiting:
Is it justified? Anesthesiology 97:287, 2002.
716.
Bailey P, Norton R, Karan S: The FDA droperidol
warning: Is it justified? Anesthesiology 97:288–289, 2002.
717.
Flood P, Coates KM: Droperidol inhibits GABA(A)
and neuronal nicotinic receptor activation. Anesthesiology 96:987–993, 2002.
718.
Borison HL, Wang SC: Physiology and pharmacology
of vomiting. Pharmacol Rev 5:193–230, 1953.
719.
Janssen P: Zur Frage des Abbaus und der Ausscheidung
der bei Neuroleptanalgesie zur Anwendung kommenden Pharmaka. In
Henschel W (ed): Die Neuroleptanalgesie. Berlin, Springer-Verlag, 1966.
720.
Michenfelder JD, Theye RA: Effects of fentanyl,
droperidol, and Innovar on canine cerebral metabolism and blood flow. Br J Anaesth
43:630–636, 1971.
721.
Barker J, Harper A, McDowall D: Cerebral blood
flow, cerebrospinal fluid pressure and EEG activity during neuroleptanalgesia induced
with dehydrobenzperidol and phenoperidine. Br J Anaesth 40:143, 1968.
722.
Song D, Chung F, Yogendran S, Wong J: Evaluation
of postural stability after low-dose droperidol in outpatients undergoing gynaecological
dilatation and curettage procedure. Br J Anaesth 88:819–823, 2002.
723.
Corssen G, Domino EF, Sweet RB: Neuroleptanalgesia
and anesthesia. Anesth Analg 43:748–763, 1964.
724.
Wooltorton E: Droperidol: Cardiovascular toxicity
and deaths. CMAJ 166:932, 2002.
725.
Yelnosky J, Katz R, Dietrich EV: A study of some
of the pharmacologic actions of droperidol. Toxicol Appl Pharmacol 6:37–47,
1964.
726.
Janssen P, Niemegeers C, Schellekens K: The pharmacology
of dehydrobenzperidol, a new potent and short acting neuroleptic agent chemically
related to haloperidol. Arzneimittelforschung 13:205–211, 1963.
727.
Stanley T: Cardiovascular effects of droperidol
during enflurane and enflurane-nitrous oxide anaesthesia in man. Can Anaesth Soc
J 25:26–29, 1978.
728.
Birch AA, Boyce WH: Effects of droperidol-dopamine
interaction on renal blood flow in man. Anesthesiology 47:70–71, 1977.
729.
Wetchler B, Collins I, Jacob L: Antiemetic effects
of droperidol on the ambulatory surgery patient. Anesthesiol Rev 9:23, 1982.
730.
Pandit SK, Kothary SP, Pandit UA, et al: Dose-response
study of droperidol and metoclopramide as antiemetics for outpatient anesthesia.
Anesth Analg 68:798–802, 1989.
731.
Kymer PJ, Brown RE Jr, Lawhorn CD, et al: The
effects of oral droperidol versus oral metoclopramide versus both oral droperidol
and metoclopramide on postoperative vomiting when used as a premedicant for strabismus
surgery. J Clin Anesth 7:35–39, 1995.
732.
Hill RP, Lubarsky DA, Phillips-Bute B, et al:
Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol,
or placebo. Anesthesiology 92:958–967, 2000.
733.
McKenzie R, Tantisira B, Jackson D, et al: Antiemetic
efficacy of a droperidol-morphine combination in patient-controlled analgesia. J
Clin Anesth 7:141–147, 1995.
734.
Aldrete JA: Reduction of nausea and vomiting
from epidural opioids by adding droperidol to the infusate in home-bound patients.
J Pain Symptom Manage 10:544–547, 1995.
735.
Kjellberg F, Tramer MR: Pharmacological control
of opioid-induced pruritus: A quantitative systematic review of randomized trials.
Eur J Anaesthesiol 18:346–357, 2001.
